Riskpilot← Back to searchSign inGet full accessDalapharm Consulting AB
ABActiveOrg 5593656084Skålmyrsvägen 33Activities of employment placement agencies · NACE 7810Est. 20225-9 employees
Revenue 2024
SEK 5,5M
+27% vs 2023
EBITDA margin
12.6%
-9% vs 2023
Equity ratio
62.5%
Financial strength
Net profit 2024
SEK 548K
-10% vs 2023
| Revenue | SEK 5,5M | +27% |
| EBITDA | SEK 695K | -9% |
| Net profit | SEK 548K | -10% |
| Total assets | SEK 2M | -8% |
| Equity | SEK 1,2M | +32% |
| Employees | — | — |
Legal name
Dalapharm Consulting AB
Org number
5593656084
Legal form
Aktiebolag
NACE code
7810 · Activities of employment placement agencies
Founded
15 februari 2022
Share capital
SEK 25 000
Employees
5-9
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Föremålet för bolagets verksamhet är att bedriva bemanning av farmaceuter inom apotek, vård, utbildning, life science och därmed förenlig verksamhet.
Address
Skålmyrsvägen 33
Email
kontakt@dalapharm.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | 715 | 4 359 | 5 531 |
| Staff expenses | −328 | −2 766 | −4 466 |
| EBITDA | 378 | 763 | 695 |
| Depreciation & amort. | — | — | — |
| EBIT | 378 | 763 | 695 |
| Net financials | 0 | 2 | −1 |
| Profit before tax | 378 | 765 | 694 |
| Tax | −78 | −159 | −146 |
| Net profit | 300 | 607 | 548 |
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Total assets | 312 | 2 137 | 1 967 |
| Equity | 325 | 932 | 1 230 |
| Long-term debt | — | — | — |
| Short-term debt | −13 | 1 205 | 737 |
| Total debt | −13 | 1 205 | 737 |
EBITDA margin
12.6%
This company
15.8%
Market median
-20% vs market
20222024
Equity ratio
62.5%
This company
38.2%
Market median
+64% vs market
20222024
Return on equity
44.6%
This company
18.4%
Market median
+142% vs market
20222024
Net profit margin
9.9%
This company
8.1%
Market median
+22% vs market
20222024
Asset turnover
2.81×
This company
1.12×
Market median
+151% vs market
20222024
Debt / equity
0.60×
This company
0.62×
Market median
+3% vs market
20222024
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
JM Audit | Audit | 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Deputy Board Member | 2024 | |
| Board of Directors | 2022 | |
| Chairman | 2022 | |
| Former (5) | ||
| Board of Directors | 2022 – 2024 | |
| Chairman | 2022 – 2022 | |
| Board of Directors | 2022 – 2022 | |
| Deputy Board Member | 2022 – 2022 | |
| Deputy Board Member | 2022 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Dalapharm Consulting AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jonas Martin Dahlin | Audit | 0 companies |
| Karam Salah Polus Deesha | Board of Directors | 0 companies |
| M H Charlotte Wiberg Larsson | Chairman | 0 companies |
| Bo Torsten Nilsson | Board of Directors | 0 companies |
| Anders Nguyen | Deputy Board Member | 0 companies |
| Alex Nordqvist | Board of Directors | 0 companies |
| Peter Jonas Michael Carlborg | Deputy Board Member | 0 companies |
| Mansoor Nasiri | Chairman | 0 companies |
| Bo Torsten Patrik Nilsson | Deputy Board Member | 0 companies |